

Bone Marrow Dosimetry and Safety of High ^{131}I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer

Bart de Keizer, MD¹; Anne Hoekstra, MsC¹; Mark W. Konijnenberg, MsC²; Filip de Vos, MsC³; Bieke Lambert, MsC³; Peter P. van Rijk, MD, PhD¹; Cees J.M. Lips, MD, PhD⁴; and John M.H. de Klerk, MD, PhD¹

¹Department of Nuclear Medicine, Utrecht University Medical Center, Utrecht, The Netherlands; ²Research and Development, Mallinckrodt, Tyco Healthcare, Petten, The Netherlands; ³Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium; and ⁴Department of Endocrinology, Utrecht University Medical Center, Utrecht, The Netherlands

Recombinant human thyroid-stimulating hormone (rhTSH) recently was introduced as a radioiodine administration adjunct that avoids levothyroxine (LT-4) withdrawal and resultant hypothyroidism. The pharmacokinetics of ^{131}I after rhTSH administration are known to differ from those after LT-4 withdrawal but are largely nondelineated in the radioiodine therapy setting. We therefore sought to calculate the red marrow absorbed dose of high therapeutic activities of ^{131}I given after rhTSH administration to patients with metastatic or inoperable locally recurrent differentiated thyroid cancer. We also sought to evaluate the clinical and laboratory effects of this therapy on the bone marrow. **Methods:** Fourteen consecutive patients received in total 17 ^{131}I treatments (7.4 GBq). Blood and urine samples were obtained at fixed intervals, and their activities were measured in a well counter. Based on blood activity, renal clearance of the activity, and residence times in red marrow and the remainder of the body, the red marrow absorbed dose was calculated using the MIRD schema. Additionally, we monitored for potential hematologic toxicity and compared platelet counts before and 3 mo after treatment. **Results:** The mean \pm SD absorbed dose per unit of administered ^{131}I in the red marrow was 0.16 ± 0.07 mGy/MBq. The corresponding total red marrow absorbed dose was 1.15 ± 0.52 Gy (range, 0.28–1.91 Gy). In none of the patients was hematologic toxicity observed. The mean \pm SD platelet count ($n = 13$ treatments) was $243 \pm 62 \times 10^9/\text{L}$ before treatment and $233 \pm 87 \times 10^9/\text{L}$ 3 mo later, a slight and statistically insignificant decrease. After rhTSH-aided administration of high activities of ^{131}I , the bone marrow absorbed dose remained under 2 Gy, the level long considered the safety threshold for all radioiodine therapy. **Conclusion:** Our specific findings imply that when clinically warranted, rhTSH should allow an increase in the therapeutic radioiodine activity. Such an increase might improve efficacy

while preserving safety and tolerability; this possibility should be assessed in further studies.

Key Words: thyroid cancer; radioiodine; recombinant thyroid-stimulating hormone; bone marrow dosimetry

J Nucl Med 2004; 45:1549–1554

Administration of high dosages of ^{131}I is widely recommended as a treatment for metastatic and inoperable locally recurrent differentiated thyroid cancer (DTC) (1–3). In thyroidectomized patients, increased thyroid-stimulating hormone levels are necessary to maximize selective radioiodine uptake by neoplastic cells and traditionally have been obtained by withdrawing levothyroxine (L-T4) for 4–6 wk. However, L-T4 withdrawal typically induces symptoms of hypothyroidism that often physically and psychologically constrain active people for prolonged periods (4).

The availability of recombinant human thyroid-stimulating hormone (rhTSH) provides an alternative means to elevate the thyroid-stimulating hormone level without inducing hypothyroidism. In the United States and Europe, rhTSH is approved for use before thyroglobulin testing or diagnostic ^{131}I scintigraphy in patients on L-T4 suppressive therapy. In addition, several reports have been published on the efficacy of rhTSH before administration of therapeutic activities of ^{131}I (5–7).

As is the case with most radiopharmaceuticals, with radioiodine the bone marrow absorbed dose is one of the major factors limiting the size of the therapeutic activity that may be administered to a given patient. To calculate the bone marrow absorbed dose and, thus, the maximum tolerated activity for an individual, an understanding of the pharmacokinetics of large activities of ^{131}I is necessary. Such pharmacokinetics are well characterized in patients whose LT-4 has been withdrawn and who have become hypothyroid (8,9). However, though it is known that the

Received Nov. 13, 2003; revision accepted Mar. 10, 2004.

For correspondence or reprints contact: Bart de Keizer, Department of Nuclear Medicine, University Medical Center Utrecht, Room E02.222, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

E-mail: b.dekeizer@azu.nl

pharmacokinetics of ^{131}I after rhTSH administration differ from those during hypothyroidism (10–12), these pharmacokinetics remain largely nondelineated with respect to large activities of radioiodine. To our knowledge, blood dosimetry of therapeutic activities of ^{131}I has been reported only to a limited degree in 2 single-case reports (13,14). We therefore conducted the present study to calculate the red marrow and whole-blood absorbed doses of large activities of ^{131}I given after administration of rhTSH. In addition, we sought to evaluate the effects of rhTSH-aided radioiodine treatment on the bone marrow by monitoring for potential related hematologic toxicity and by comparing baseline and posttreatment platelet counts.

MATERIALS AND METHODS

Patients

Patient characteristics are shown in Table 1. In total, 14 consecutive adult patients with metastatic ($n = 12$ patients, 13 treatments) or inoperable locally recurrent ($n = 2$ patients, 4 treatments) DTC were treated in 2 academic hospitals, 11 patients (treatments 1–14) at the University Medical Center in Utrecht, The Netherlands, and 3 (treatments 15–17) at the Ghent University Hospital, Belgium. Two patients were treated more than once (treatments 3, 6, and 10 and treatments 8 and 13), resulting in a total of 17 treatments for the series. Eight of 14 patients were female and 13 of 14, ≥ 64 y old.

Before study entry, all patients had undergone total or near-total thyroidectomy followed by thyroid remnant ablation with a large activity of ^{131}I . After ablation, 12 patients also had received one or more therapeutic activities of radioiodine after L-T4 withdrawal. Previous posttherapy scintigraphy showed pathologic ^{131}I accumulation in metastatic or locally recurrent lesions in all patients. The

study was approved by the local ethics committee, and all patients gave written informed consent to participate. Tumor dosimetry and response after rhTSH-aided radioiodine treatment in these patients have been reported elsewhere (7).

Treatment Protocol

Patients were instructed to follow a low-iodine diet for the 5 d before and 2 d after ^{131}I administration. An intramuscular injection of rhTSH (0.9 mg) (Thyrogen; Genzyme Corp.) was given on 2 consecutive days, followed by oral administration of 7.4 GBq of ^{131}I (Tyco Healthcare) on the third day. Treatment was given on an inpatient basis; patients were discharged 3 d after oral administration of the ^{131}I , after the final collection of blood and urine samples.

Bone Marrow Dosimetry

Immediately before and at 1, 2, 4, 8, 24, 48, and 72 h after ^{131}I administration, blood samples were drawn. In addition, urine was collected for the 72 h after radioiodine administration. The radioactivity of blood and urine samples and of a standard of known activity was measured in a well counter (Sample Changer type 5550; Packard Bioscience Co.). The blood data points were fitted to a biexponential time–activity–concentration function. For the second exponential function, a half-life of 80 d was used for ^{131}I in thyroactive tissue. Use of this model recirculation of ^{131}I is accounted for (15). It was assumed that the activity concentration in the red bone marrow could be estimated by the activity concentration in blood, using the patient-specific method of Sgouros (16,17), as the Na^{131}I does not bind to marrow or bone. The circulating blood activity produces a red marrow dose, D_{RM} , of:

$$D_{\text{RM}}^{\text{blood}} = A_0[\tau]_{\text{blood}} m_{\text{RM}}^{\text{model}} \frac{m_{\text{TB}}^{\text{patient}}}{m_{\text{TB}}^{\text{model}}} \frac{\text{RMECFF}}{1 - \text{HCT}} S(\text{RM} \leftarrow \text{RM}), \quad \text{Eq. 1}$$

TABLE 1
Patient Characteristics

Treatment	TNM stage at diagnosis	Site of metastatic lesions	Sex	Age at therapy (y)	DTC histology	Number of previous ^{131}I therapies*
1	Tx N0 M0	Lymph node neck	F	82	Papillary	5 (35.1)
2	T4 N0 M0	Lung	F	70	Follicular	3 (18.4)
3†	T4 N0 M0	Local recurrence	M	78	Follicular	7 (48.1)
4	Tx N1 M0	Lung	M	67	Follicular	4 (27.7)
5	T4 N0 M1	Lung/mediastinum	M	83	Follicular	2 (11.1)
6†	T4 N0 M0	Local recurrence	M	79	Follicular	8 (55.5)
7	T3 N0 M1	Lung, liver, and bone	F	70	Follicular	2 (14.8)
8‡	T4 N0 M1	Lung	F	72	Follicular	1 (3.7)
9	Tx N0 M0	Skull	M	71	Follicular	3 (14.8)
10†	T4 N0 M0	Local recurrence	M	79	Follicular	9 (62.9)
11	T2 N0 M0	Lymph node neck	F	64	Papillary	2 (11.1)
12	Tx N0 M0	Lymph node neck	F	87	Papillary	1 (3.7)
13‡	T4 N0 M1	Lung	F	73	Follicular	2 (11.1)
14	T4 N0 M0	Lung	F	73	Follicular	1 (3.7)
15	T2 N0 M1	Lung	M	70	Papillary	2 (14.8)
16	T4 N1 M1	Lymph node neck	F	41	Papillary	2 (12.9)
17	T4 N0 M0	Lung	M	78	Follicular	2 (12.9)

*Includes thyroid remnant ablation. Cumulative activity, in gigabecquerels, is in parentheses.

†Patient received 3 rhTSH-aided treatments.

‡Patient received 2 rhTSH-aided treatments.

where A_0 is the injected activity, $[\tau]_{\text{blood}}$ is the residence time of the blood concentration (in h/L), $m_{\text{RM}}^{\text{blood}}$ is the red marrow mass according to the bone marrow model (1.120 kg (18)), and $m_{\text{TB}}^{\text{patient}}$ and $m_{\text{TB}}^{\text{model}}$ are the total body masses of the patient and according to the dosimetry model (MIRD: 73.7 kg (19)), respectively. The red marrow extracellular fluid fraction, RMECF ($=0.19$ (16)), divided by $1 - \text{HCT}$, the hematocrit (volume fraction of red blood cells), expresses the ratio of red marrow concentration to blood concentration, which usually lies between 0.2 and 0.4. The red marrow self-dose S-value, $S(\text{RM} \leftarrow \text{RM})$, for ^{131}I (1.55×10^5 mGy/MBq·s) was obtained from the RADAR (Radiation Dose Assessment Resource) Web site (20).

The whole-body activity equals the administered activity minus the excreted activity. These data points also were fitted to a biexponential time–activity function. Because the contribution of the activity in the bone marrow to the whole-body activity is small, the activity in the remainder of the body (A_{rem}) was assumed to equal the whole-body activity: $A_{\text{rem}}(t) = A_h \{a_1 \exp(-\lambda_{1,\text{rem}}t) + a_2 \exp(-\lambda_{2,\text{rem}}t)\}$, where A_h is the initial whole-body activity and $\lambda_{i,\text{rem}}$ the whole-body clearance constants with relative contributions a_i (for $i = 1, 2$).

The dose to the red marrow from the whole-body distribution was estimated by the patient-specific method of Shen et al. (17):

$$D_{\text{RM}}^{\text{TB}} = A_0 \tau_{\text{TB}} \frac{m_{\text{TB}}^{\text{model}}}{m_{\text{TB}}^{\text{patient}}} S(\text{RM} \leftarrow \text{TB}), \quad \text{Eq. 2}$$

where τ_{TB} is the total-body residence time ($=A_h/A_0((a_1/\lambda_{1,\text{rem}} + \lambda_p) + (a_2/\lambda_{2,\text{rem}} + \lambda_p))$, with λ_p the physical decay constant for ^{131}I) and $S(\text{RM} \leftarrow \text{TB})$ is the total-body–to–red-marrow S-value. Depending on whether bone metastases were observed, the total-body MIRD-based S-value was corrected for the bone component according to the method of Stabin et al. (21), yielding $S(\text{RM} \leftarrow \text{TB}) = 2.78 \times 10^7$ mGy/MBq·s without and $S(\text{RM} \leftarrow \text{TB}) = 4.04 \times 10^7$ mGy/MBq·s with uptake in the bone surfaces. Because no patients in this study showed evidence of diffuse uptake in the skeleton, only the first S-value was used for the radiation doses to the patients.

Whole-Blood Dose Calculations

The blood dose was calculated according to the method of Benua et al. (8). On the basis of the previously calculated cumulative blood activity, it was assumed for our patient population that 37 MBq/d/L of ^{131}I delivered to the blood a β -dose of 10 cGy (assuming complete absorption) and a γ -dose of 20.4 cGy (assuming an absorption factor of 0.4).

Safety Assessment

Physician observation and patient reporting of adverse events were used to assess the safety and impact on the bone marrow of rhTSH-aided radioiodine treatment. Additionally, standard serum platelet counts were taken before and 3 mo after rhTSH-aided radioiodine treatment.

Statistical Analysis

Descriptive statistics were calculated for bone marrow, whole blood, and urinary dosimetry; urine excretion; and platelet count. All mean values are expressed as mean \pm SD. Mean platelet counts before and after rhTSH-aided treatments were compared by a paired-sample t test using SPSS (version 11; SPSS Inc.) for Windows (Microsoft). A P value < 0.05 was considered significant.

RESULTS

The bone marrow and whole-blood dosimetry and urine and urinary ^{131}I excretion in each patient are shown in Table 2. The calculated mean \pm SD absorbed dose in the red bone marrow, expressed as dose per unit of administered ^{131}I , was 0.16 ± 0.07 mGy/MBq for our patient group. The mean total bone marrow absorbed dose was 1.15 ± 0.52 Gy (median, 1.15 Gy; range, 0.28–1.91 Gy).

The mean whole-blood absorbed dose per unit of administered ^{131}I was 0.23 ± 0.04 mGy/MBq. The mean total blood dose was 1.69 ± 0.34 Gy (median, 1.67 Gy; range, 1.09–2.27 cGy). Four patients had a whole-blood absorbed dose exceeding 200 cGy (treatments 2, 5, 9, and 12).

The mean residence time was 134 ± 60 h (median, 132 h; range, 17–231 h).

Pretreatment with rhTSH was very well tolerated. No serious or marrow-related side effects were noted. After ^{131}I administration, a transient period of mild nausea was observed for 6 of 17 treatments. The nausea was treated with antiemetic drugs (8 mg of ondansetron) and resolved within 5 d in all cases. In addition, sialoadenitis of the parotid gland developed in 1 patient but quickly resolved after treatment with acetylsalicylic acid.

Pre- and posttreatment platelet counts were available for 13 treatments (10 patients). The mean platelet count before therapy was $243 \pm 62 \times 10^9/\text{L}$. Three months after therapy, the mean platelet count slightly decreased to $233 \pm 87 \times 10^9/\text{L}$, but this change was not statistically significant ($P = 0.418$). Over the 3-mo follow-up, platelet counts decreased after 8 treatments but increased after 5 (Table 3).

DISCUSSION

The bone marrow absorbed dose after treatment with large activities of ^{131}I would be expected to be lower for patients given rhTSH, and therefore remaining euthyroid, than for patients subjected to L-T4 withdrawal and resultant hypothyroidism. The main explanation for this phenomenon lies in the lower renal clearance for hypothyroid patients than for euthyroid patients.

Changes in renal function are common during hypothyroidism, and an increased serum creatine and decreased glomerular filtration rate have been described (22). Decreased renal clearance would be expected to result in increased ^{131}I retention, and indeed, Park et al. (10) reported that radioiodine retention after diagnostic ^{131}I imaging was 50% greater in patients after withdrawal of L-T4 than in patients receiving rhTSH.

Another possible explanation for the differences in ^{131}I pharmacokinetics between rhTSH administration and thyroid hormone withdrawal was offered by Menzel et al. (11). They recently demonstrated that rhTSH reduced the whole-body effective half-life of ^{131}I after treatment with large activities, compared with observations for a separate cohort from whom thyroid hormone was withdrawn. Hypothyroid patients may have greater physiologic retention of radioio-

TABLE 2
Bone Marrow and Whole-Blood Dosimetry and Residence Times

Treatment	Residence time (TB [h])	Patient-specific bone marrow dosimetry* (D _{BM})		Blood model dosimetry† (D _{BL})	
		Gy	mGy/MBq	Gy	mGy/MBq
1	156	1.14	0.154	1.49	0.202
2	173	1.91	0.259	2.10	0.285
3‡	155	1.20	0.166	1.37	0.190
4	63	0.46	0.063	1.09	0.149
5	98	0.89	0.120	2.04	0.276
6‡	208	1.64	0.218	1.78	0.237
7	132	0.96	0.129	1.42	0.244
8§	17	0.28	0.052	1.56	0.211
9	231	1.70	0.230	2.25	0.304
10‡	196	1.82	0.240	1.76	0.233
11	72	0.62	0.083	1.26	0.171
12	98	0.93	0.120	2.27	0.294
13§	162	1.50	0.202	1.95	0.263
14	48	0.36	0.049	1.55	0.210
15	123	1.15	0.155	1.70	0.229
16	177	1.59	0.215	1.43	0.194
17	161	1.43	0.193	1.67	0.226
Mean ± SD	134 ± 60	1.15 ± 0.52	0.16 ± 0.07	1.69 ± 0.34	0.23 ± 0.04

*Calculated according to MIRD method of Sgouros and Shen (15,16,18).

†Calculated according to method of Benua et al. (8).

‡Patient received 3 rhTSH-aided treatments.

§Patient received 2 rhTSH-aided treatments.

D_{BL} = blood dose.



TABLE 3
Platelet Counts

Treatment	Pretreatment platelet count (×10 ⁹ /L)	3-mo posttreatment platelet count (×10 ⁹ /L)	Change between pretreatment and 3-mo counts (%)
1	203	158	−22
2	306	251	−18
3*	197	152	−23
4	283	233	−18
5	172	140	−19
6*	175	146	−17
7	316	400	+27
8‡	264	306	+16
9	210	203	−3
10*	154	165	+7
11	338	343	+1
12	236	196	−17
13‡	305	337	+10
14	NP	NP	—
15	NP	NP	—
16	NP	NP	—
17	NP	NP	—

*Patient received 3 rhTSH-aided treatments.

‡Patient received 2 rhTSH-aided treatments.

NP = not performed.

dine in the gastrointestinal tract (and presumably, other sites as well), as suggested by anecdotal impressions of greater background-to-noise ratios in posttherapy scintigrams taken after thyroid hormone withdrawal (11).

Our findings after 17 treatments given to 14 patients with metastatic or locally recurrent DTC suggest that the bone marrow absorbed dose indeed is lower after rhTSH-aided treatment than historically has been observed after thyroid hormone withdrawal-aided treatment. Although we calculated the red marrow absorbed dose using the MIRD schema, we also calculated the whole-blood radiation-absorbed dose by the approach of Benua et al. (8) to permit a comparison with historical data. We found a lower mean whole-blood dose per administered activity of ^{131}I in our series than Benua et al. did in 59 patients with metastatic DTC receiving a total of 122 radioiodine treatments: 0.23 mGy/MBq versus 0.31 mGy/MBq (2.67 Gy; range, 0.45–7.40 Gy). Benua et al. observed serious complications such as nonfatal and fatal bone marrow depression, radiation pneumonitis, and vomiting persisting 30 d after 11% of treatments. Serious complications correlated with total blood radiation exceeding 2 Gy and with administration of >11 GBq of ^{131}I per individual treatment. By contrast, our patients showed no severe radiation complications. Nausea and vomiting were mild and resolved within 5 d after treatment in all affected patients. In addition to the lower whole-blood absorbed dose, the superior safety profile seen in our series may be due to the activities that we administered. Although Benua et al. gave activities sometimes exceeding 11.1 GBq, we administered relatively conservative empiric activities of 7.4 GBq as standard treatment.

In therapy using radionuclides, a red marrow absorbed dose of 2 Gy is considered dose limiting (less than 5% damage in 5 y) (23). Our study showed that the bone marrow absorbed dose after rhTSH-aided administration of large activities of ^{131}I fell below this threshold in all treatments. More important, in none of the patients was a clinically relevant bone marrow toxicity observed (only a slight, insignificant decrease in platelet counts after 3 mo). Blood tests were not performed within the 3-mo interval, and we therefore realize that a transient decline in platelet counts could have been missed. However, no intermediate-term (3 mo) hematologic side effects were observed.

In patients with a relatively high residence time (Table 2), a lower ^{131}I clearance was observed; consequently, these patients had a higher red marrow dose delivered by whole-body activity. In our opinion, patients should be advised to drink at least 2 L of liquid per day to stimulate ^{131}I clearance and thus decrease the whole-body exposure.

Our patient group had a mean red marrow absorbed dose of 0.16 mGy/MBq of administered ^{131}I . This absorbed dose would allow a therapeutic activity of ^{131}I higher than the current 7.4 GBq maximum that many centers allow for patients undergoing thyroid hormone withdrawal. This finding may have important therapeutic consequences, because a higher administered activity might well increase the tumor

absorbed dose and thus therapeutic efficacy. Further studies are merited to test this hypothesis.

CONCLUSION

In the radioiodine therapy of DTC, a bone marrow absorbed dose of 2 Gy has long been considered the safety threshold that limits the amount of ^{131}I activity that can be given. Our study showed that after rhTSH-aided administration of high activities of ^{131}I , the bone marrow absorbed dose remained below the 2-Gy threshold in all patients and treatments. More important, no clinically relevant side effects were observed using administered activities of up to 7.4 GBq of ^{131}I . Our specific dosimetric findings of a mean red marrow absorbed dose of 0.16 mGy/MBq per administered unit of ^{131}I indicate that when clinically warranted, rhTSH should allow an increase in the therapeutic radioiodine activity. Such an increase might improve efficacy while preserving safety and tolerability; this possibility should be assessed in further studies.

ACKNOWLEDGMENTS

This work was supported in part by Genzyme B.V. Netherlands, Naarden, The Netherlands. We are grateful to Rob Marlowe, Klaus Bacher, and Rudi Dierckx for their constructive critical reading and remarks.

REFERENCES

1. Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. *Semin Nucl Med.* 1978;8:79–94.
2. Schlumberger MJ, Torlantino M. Papillary and follicular thyroid carcinoma. *Baillieres Best Pract Res Clin Endocrinol Metab.* 2000;14:601–613.
3. Mazzaferrri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. *Medicine (Baltimore).* 1977;56:171–196.
4. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. *Thyroid.* 1997;7:613–619.
5. Lippi F, Capezone M, Angelini F, et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. *Eur J Endocrinol.* 2001;144:5–11.
6. Luster M, Lassmann M, Haenschel H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* 2000;85:3640–3645.
7. de Keizer B, Brans B, Hoekstra A, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. *Eur J Nucl Med Mol Imaging.* 2003;30:367–373.
8. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *AJR.* 1962;87:171–182.
9. Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan G, eds. *Frontiers in Thyroidology*. New York, NY: Plenum Medical Book Co; 1986:1317–1321.
10. Park SG, Reynolds JC, Brucker-Davis F, et al. Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant TSH (rhTSH) vs. hypothyroidism [abstract]. *J Nucl Med.* 1996;37(suppl):15P.
11. Menzel C, Kranert WT, Dobert N, et al. RhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of I-131. *J Nucl Med.* 2003;44:1065–1068.
12. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone

- and after thyroid hormone withdrawal in thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2003;30:1371–1377.
13. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. *Thyroid*. 2000;10:767–778.
 14. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. *J Clin Endocrinol Metab*. 2000;85:237–244.
 15. Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. *Cancer Biother Radiopharm*. 2003;18:445–450.
 16. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. *J Nucl Med*. 1993;34:689–694.
 17. Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. *J Nucl Med*. 2002;43:1245–1253.
 18. Eckerman KF, Stabin MG. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. *Health Phys*. 2000;78:199–214.
 19. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. *J Nucl Med*. 1996;37:538–546.
 20. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. *Health Phys*. 2003;85:294–310.
 21. Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method. *J Nucl Med*. 2001;42:492–498.
 22. Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I. Changes in renal function in primary hypothyroidism. *Am J Kidney Dis*. 1996; 27:195–198.
 23. Scala RJ. Biologic effects of ionizing radiation. In: Early PJ, Sodee BD, eds. *Principles and Practice of Nuclear Medicine*. St Louis, MO: Mosby; 1995:123–127.





The Journal of
NUCLEAR MEDICINE

Bone Marrow Dosimetry and Safety of High ^{131}I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer

Bart de Keizer, Anne Hoekstra, Mark W. Konijnenberg, Filip de Vos, Bieke Lambert, Peter P. van Rijk, Cees J.M. Lips and John M.H. de Klerk

J Nucl Med. 2004;45:1549-1554.

This article and updated information are available at:
<http://jnm.snmjournals.org/content/45/9/1549>

Information about reproducing figures, tables, or other portions of this article can be found online at:
<http://jnm.snmjournals.org/site/misc/permission.xhtml>

Information about subscriptions to JNM can be found at:
<http://jnm.snmjournals.org/site/subscriptions/online.xhtml>

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2004 SNMMI; all rights reserved.